On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2014: Volume 19/ Issue 33 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 19, Issue 33, 21 August 2014
Research articles
Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012
  1. Centre for Infectious Diseases Research, Diagnostics and Screening (IDS), Centre for Infectious Diseases Control (CIb), National Institute of Public Health and the Environment (RIVM), the Netherlands
  2. Swedish Institute for Communicable Disease Control, Solna, Sweden
  3. Institut für Hygiene und Labormedizin, Krefeld, Germany
  4. Norwegian Institute of Public Health, Oslo, Norway
  5. Statens Serum Institut, Copenhagen, Denmark
  6. Public Health England, London, United Kingdom
  7. National Institute for Health and Welfare, Turku, Finland
  8. Turku University Hospital, Department of Pediatrics, Turku, Finland

Citation style for this article: Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von König CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F. Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012. Euro Surveill. 2014;19(33):pii=20881. Article DOI:
Date of submission: 12 November 2013

Pathogen adaptation has been proposed to contribute to the resurgence of pertussis. A striking recent example is the emergence of isolates deficient in the vaccine component pertactin (Prn). This study explores the emergence of such Prn-deficient isolates in six European countries. During 2007 to 2009, 0/83 isolates from the Netherlands, 0/18 from the United Kingdom, 0/17 Finland, 0/23 Denmark, 4/99 Sweden and 5/20 from Norway of the isolates collected were Prn-deficient. In the Netherlands and Sweden, respectively 4/146 and 1/8 were observed in a later period (2010–12). The Prn-deficient isolates were genetically diverse and different mutations were found to inactivate the prn gene. These are indications that Prn-deficiency is subject to positive selective pressure. We hypothesise that the switch from whole cell to acellular pertussis vaccines has affected the balance between ‘costs and benefits’ of Prn production by Bordetella pertussis to the extent that isolates that do not produce Prn are able to expand. The absence of Prn-deficient isolates in some countries may point to ways to prevent or delay the spread of Prn-deficient strains. In order to substantiate this hypothesis, trends in the European B. pertussis population should be monitored continuously.


Introduction of whole cell pertussis vaccines (WCVs) 50 to 60 years ago has greatly reduced the pertussis burden worldwide [1]. However, despite a vaccine coverage between 80% and 96%, pertussis has resurged in many countries [2,3]. In particular, in the last few years, high incidences have been observed in the Netherlands, the United Kingdom (UK) and the United States (US) [4-6]. Several causes have been proposed for the resurgence of pertussis, including waning immunity and pathogen adaptation [7].

In the 1990s, less-reactive acellular pertussis vaccines (ACVs) replaced WCVs. ACVs contain between one and five pertussis proteins: (i) pertussis toxin (Ptx); (ii) pertactin (Prn); (iii) serotype 2 fimbriae (Fim2); (iv) serotype 3 fimbriae (Fim3); and (v) filamentous haemagglutinin (FHA). All ACVs contain Ptx. The effectiveness of the different available WCVs was highly variable [8], which complicates evaluation of the protection that ACVs induce compared with that of WCVs. However, recently, several studies have indicated that the immunity induced by ACVs is less long-lasting compared with effective WCVs, resulting in a higher pertussis burden, particularly in children aged 6 to 10 years [9-12].

The effect of waning immunity may have been aggravated by pathogen adaptation [7], which is reflected in large shifts in Bordetella pertussis populations [13-15]. Observed adaptations include antigenic divergence between circulating strains and vaccine strains, and the emergence of strains with a novel promoter for Ptx (ptxP3) [16]. In addition, most recently, strains have emerged that do not express Prn, hereafter named Prn-deficient strains [17-22]. Isolates with the ptxP3 promoter increased in frequency in the 1980s and at present they predominate in many countries, reflecting a global selective sweep [6,13,16,23-26]. The ptxP3 isolates produce higher amounts of Ptx in vitro (1.6-fold increase), when compared with the ptxP1 isolates they replaced [16]. It has been suggested that this may result in a more effective suppression of host immunity [16]. In agreement with this, ptxP3 isolates reach higher bacterial densities than ptxP1 isolates in mice [27]. Prn-deficient isolates emerged around 2000 and have been found in Finland, France, Japan and the US [18-20,22]. In addition, less frequently, isolates were found that do not produce FHA or Ptx. Hegerle et al. reported one isolate lacking both Prn and FHA, and one isolate lacking Ptx [17,19]. Bouchez et al. have suggested that the emergence of such isolates is related to the introduction of ACVs [17,28]. Prn-deficient isolates have been isolated from pertussis patients and seemed to be as virulent as isolates expressing Prn in infants less than six months of age as well as in a mouse model [17,29]. A better understanding of the epidemiology and virulence of Prn-deficient isolates is crucial for the development of next-generation pertussis vaccines.

In this study, we investigated the emergence and spread of Prn-deficient isolates in Europe. To do so, we combine single nucleotide polymorphism (SNP) typing, antigen expression analysis and DNA sequencing with epidemiological data. The diversity of vaccination programmes in Europe (Table 1) offers a unique opportunity to study the effect, if any, of vaccination policy on the emergence of Prn-deficient strains. Ultimately, we aim to define conditions that could prevent or hamper the emergence of vaccine-adapted strains. This study provides a baseline for future European studies in which the occurrence and spread of Prn-deficient strains will be investigated.

Table 1. Year of introduction, vaccine composition and vaccination coverage of acellular pertussis vaccines in six European countries


Analysis of Bordetella pertussis isolates
Six countries provided a total of 665 strains isolated from nasopharyngeal swabs from confirmed pertussis patients for this study: Denmark (n=43), Finland (n=56), Netherlands (n=311), Norway (n=20), Sweden (n=197) and the UK (for the purposes of this article, the UK is considered as one country) (n=38) (Table 2). These countries were selected as they are members of European research programme for improved pertussis strain characterisation and surveillance (EUPERTSTRAIN) network and were able to contribute strains. The strains were isolated during 1996 to 2012. In the countries studied, primary immunisation with ACVs was introduced between 1996 and 2005 (Table 1). Furthermore, in these countries, different ACVs and different vaccine strategies were used and the vaccine coverage varied (Table 1). Strains were grouped into three periods, 1996–2006, 2007–09 and 2010–12 (periods I, II and III, respectively). Bacteria were cultured on Bordet Gengou agar plates supplemented with 15% sheep blood and incubated at 35 °C for 3 to 4 days.

Table 2. Bordetella pertussis isolates typed by single nucleotide polymorphisms and analysed for pertactin and pertussis toxin production in six European countries, 1996–2012

PCR and DNA sequencing
DNA isolation was performed using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, Zwijndrecht, the Netherlands), following the manufacturer’s instructions for Gram-negative bacteria. For multi-antigen sequence typing (MAST), the pertussis toxin promoter (ptxP), regions 1 and 2 of the pertactin gene (prn), the genes for serotype 2 fimbriae (fim2) and serotype 3 fimbriae (fim3) were sequenced in order to determine polymorphisms [16,30].

To determine the location and size of the mutation causing non-expression of Prn, four sets of primers were selected for PCR amplification of the prn gene (Table 3). Prn PCR products were visualised and sized by capillary electrophoresis on a QIAxcel instrument (Qiagen Benelux), using the QIAxcel high-resolution kit, QX DNA size marker 250–8,000 base pairs (bp) and QX alignment markers 15/8,000 bp. Each type of mutation was verified in at least one isolate by Sanger sequencing using an ABI 3700 DNA sequencer (Perkin-Elmer Applied Biosystems).

Table 3. Primers used for the characterisation of mutations leading to non-expression of pertactin in Bordetella pertussis isolates in six European countries, 1996–2012

Identification of vaccine antigen-deficient isolates
A microsphere-based Multiplex Immunoassay (Luminex, Austin, TX, US) [31] was developed to measure the expression of Ptx and Prn. Isogenic ptx (B0085) and prn (B1686) knockout strains were used as negative controls [32,33]. Analyses of these negative controls resulted in values <5 ng/ml. Therefore, isolates with antigen concentrations <5 ng/ml were considered deficient isolates. All deficient isolates were tested at least twice, starting from independent cultures. In addition, Prn deficiency was verified with an immunoblot using the monoclonal antibody Prn Ab 62, E4D7 [34] (Figure 1).

Figure 1. Immunoblot to confirm absence of pertactin (69 kD) expression in Bordetella pertussis isolates in six European countries, 1996–2012

Single nucleotide polymorphism typing and clustering analysis
SNP typing was used to establish genetic relationships between B. pertussis isolates [35,36]. A total of 113 SNPs that are useful for discriminating between isolates were selected after comparing whole genome data of a selection of 74 worldwide isolates (data not shown). In order to study the origin and spread of European Prn-deficient isolates, SNP typing was performed on 261 isolates from all six countries using the Sequenom technology (Sequenom, San Diego, CA, US) [35]. At least 40 randomly selected strains (using the function RAND in Microsoft Excel) per country were typed, if available. A tree was constructed in Bionumerics 6•6 (Applied Maths, Sint-Martens-Latem, Belgium), treating the SNPs as character data and using the neighbor-joining algorithm. The vaccine strains B0006 (from the Netherlands, 1950, ptxP2), B0499 (ACV strain 10-536, 1951, ptxP2) and B0005 (from the Netherlands, 1950, ptxP1) were included as outgroups.


Frequency of pertactin-deficient isolates in six European countries
Expression of Prn was assessed by a multiplex Immunoassay assay and immunoblotting (Figure 1) for 576 of the 665 strains from the six countries, of which 14 (2.4%) were shown to be Prn deficient (Tables 2 and 4). All 576 strains tested positive for Ptx production. For period I (1996–2006), only strains from the Netherlands (n=82) and Sweden (n=80) were available for this analysis. One Prn-deficient isolate from Finland was obtained in period I: this isolate was not included in the Prn-deficiency frequency analysis because no other Finnish isolates were analysed for Prn expression in that period. For period II (2007–09), between 17 and 99 strains from each of the six countries were analysed for Prn expression. Prn-deficient strains were observed in Norway (5/20 strains) and Sweden (4/99), but not in Denmark (0/23), Finland (0/17), the Netherlands (0/83) or the UK (0/18). As for period I, for period III (2010–12) only strains from the Netherlands (n=146) and Sweden (n=8) were available for this analysis. In that period, 4/146 Dutch strains and 1/8 Swedish strains were found to be Prn deficient. Thus, Prn-deficient isolates in the frequency analysis were detected in periods II and III. All isolates produced Ptx. The vaccination status of 14 of the 15 patients from whom the Prn-deficient isolates were recovered was unknown (Table 4). Therefore, we cannot relate the infection with a Prn-deficient strain to the degree of immunisation.

Table 4. Pertactin-deficient Bordetella pertussis isolates analysed from four European countries, 2004–12 (n=15)

Mutations causing non-expression of pertactin
Previous studies observed five types of mutations that inactivate the prn gene: inversion, deletion of (part of) the gene, insertion of IS481 into prn, insertion of a single nucleotide resulting in a frameshift mutation, or a SNP resulting in the introduction of a stop codon [17-22] (Figure 2, Table 5). We used PCR and sequencing of the prn gene to determine the cause of non-expression of the Prn-deficient isolates we analysed (Table 4). PCR fragment analysis showed that three Prn-deficient isolates (B3545, B3748, B3865) had an insertion of approximately 1 kilobase pair (kb) proximal to region 2 (Figure 3). We assumed this is the result of an insertion of IS481 into this region and no further sequencing analysis was performed on these isolates. Sequence data of the remaining 12 Prn-deficient isolates showed that in two isolates, the promoter region was inverted as described by Pawloski et al. [22]. Another three isolates (B3582, B3640, B3891) had an IS element inserted proximal to one of the two repeat regions of the prn gene, designated region 2 (Figure 2). This mutation has also been found previously in French Prn-deficient isolates [17]. Sequence data of a sixth isolate (B3771), which originated from Finland in period I, contained a deletion of 49 bases in the signal sequence. This isolate was not included in the Prn-deficiency frequency analysis because no other Finnish isolates were analysed for Prn expression in period I. The seventh isolate, B3876 from The Netherlands, contained a SNP at position 223 that introduces a premature stop codon in the prn2 gene. An eighth isolate (B3658), originating from Norway, also contained a SNP that introduces a premature stop codon in prn2, but at position 1,273. Sequencing of the prn gene around position 1,273 showed that the other four Norwegian Prn-deficient isolates also harboured this SNP.

Figure 2. Mutations in prn2 causing non-expression of pertactin in Bordetella pertussis isolates in six European countries, 1996–2012

Table 5. Mutations in the pertactin gene causing loss of pertactin expression

Figure 3. Characterisation of the prn gene from pertactin-deficient Bordetella pertussis isolates by polymerase chain reaction, from six European countries, 1996–2012

Phylogenetic relationships of European pertactin-deficient Bordetella pertussis isolates
Typing of 261 isolates from the six different European countries using 113 SNPs allowed us to distinguish 20 STs.

Phylogenetic analysis revealed a closely related European B. pertussis population (Figure 4). The tree topology showed two distinct clades containing ptxP1 and ptxP3 isolates. In addition, a fim3.1 and a fim3.2 cluster could be observed within the ptxP3 clade (Figure 4).

Figure 4. Genetic relationship between European pertactin-deficient Bordetella pertussis isolates

The 12 European Prn-deficient isolates included in the phylogenetic analyses were found in four different STs: ST13, ST14, ST17 and ST19 (Figure 4). These STs were among the predominant types and contained 70% (184/264) of the isolates analysed.

All Prn-deficient isolates analysed in this study were found in the ptxP3 clade but were associated with both fim3.1 and fim3.2 alleles. ST14 contains two types of prn mutations (Table 4). In contrast, the five Prn-deficient isolates that belong to ST13 all harboured the same mutation in prn: a SNP resulting in premature translational termination of prn. All five isolates were from Norway. The prn mutation, in which IS481 was inserted proximal to region 2, was found in three STs that were dispersed across the ptxP3 clade. This mutation was associated with both the fim3.1 and fim3.2 alleles. Thus, identical mutations were observed in different STs, while within a single ST, different mutations were found.


The diversity in immunisation programmes in Europe offers an opportunity to explore the effect of vaccination strategies on adaptation of B. pertussis in populations with a vaccine coverage between 80% and 96%. In this study, the overall mean of Prn-deficient strains from six European countries isolated between 2007 and 2012 was 3.4% (14/414 isolates). Bouchez et al. suggested that the emergence of French Prn-deficient isolates was driven by the switch from WCVs to ACVs [17]. Indeed, Prn-deficient isolates were rarely found before the introduction of ACVs, when WCVs were used [37]. Compared with the mean of Prn-deficient strains found in the six countries studied here (3.4%), higher percentages of Prn-deficient isolates were observed in France (13% in 2011), Japan (32% in 2005–09) and the US (53% in 2012) [18,19,22]. In Japan, ACVs were introduced in 1981 [18], and in the US, the first ACV was marketed in 1991. Thus, these countries have a longer history of ACV immunisation compared with the six countries included in this study, where ACVs vaccines for the primary series were introduced between 1996 and 2005 (Table 1). Interestingly, the early Prn-deficient strains found in this study were mainly from Norway and Sweden, where ACVs for the primary series were introduced in 1996 and 1998, respectively, which is earlier than in the UK (in 2000), Finland and the Netherlands (both in 2005) (Table 1). Notably, in France an ACV booster was introduced in 1998, while the WCV for the primary series was replaced with an ACV in 2004 [29]. The timing of these changes is similar to that in Norway which, as in France, has a relatively high percentage of Prn-deficient strains. In Denmark, an ACV was introduced relatively early in 1997, while Prn-deficient strains were not detected. Unlike the vaccine in the other five countries in this study, which use ACVs containing Prn (Table 1), the Danish ACV contains Ptx only. As the Danish vaccine does not induce Prn antibodies, it is conceivable that Prn-deficient strains will not emerge in Denmark, if Prn-deficiency does not contribute to strain fitness, although overflow of Prn-deficient strains from neighbouring countries is possible.

In 2007–09, five of the 20 Norwegian strains were Prn-deficient. Although the number of isolates tested was low, this proportion is relatively high compared with the overall mean of the six countries in this period (3.4%, 14/414). This implies that in Europe, besides France, Norway may also have elevated levels of Prn-deficient isolates. Comparisons of frequencies of Prn-deficient isolates should, however, be made with caution, as differences in the period investigated, vaccination policies and isolate collection are among the factors that can influence the outcome. It seems valid, though, to conclude that the fraction of Prn-deficient strains in several countries of Europe is relatively low, with the exception of France [19] and Norway, as stated above. In order to confirm these findings, further studies are required that include more isolates for each country. The analyses of larger amounts of Prn-deficient strains may also reveal if these strains are found in higher frequencies in particular age groups. Future studies should include more southern European countries.

Mutations that were previously found to inactivate the prn gene [17,19,21] were also observed in the Prn-deficient isolates analysed in this study. We found that the mutations in prn occurred several times independently in different lineages, which is an indication that it has been fixed in the population by positive selection. The European Prn-deficient isolates seem to have originated from distinct lineages, but within the diverse nature of the mutations causing non-expression, we also observed possible signs of clonal expansion of a Prn-deficient strain in Norway. Notably, the specific point mutation that occurred in five Norwegian isolates was also found in seven of 12 Prn-deficient isolates collected in Philadelphia in the US [21]. It was previously suggested that the spread of Prn-deficient isolates in Japan was the result of clonal expansion [18].

The production of bacterial virulence factors, such as pertactin, involves ‘costs and benefits’ for the bacteria. Costs include the energy used to express the virulence factors and activation of the host immune response against these antigens. Benefits comprise attachment to host tissues and manipulation of host defences. We hypothesise that the switch from WCV to ACV has affected the balance between these costs and benefits of Prn production to the extent that strains that do not produce Prn are able to expand. In support of this, our phylogenetic analysis indicates Prn-deficiency is subject to positive selection. We postulate that, because non-expression of one of the vaccine antigens contributes relatively little to immune evasion of a broad immune response, vaccination with WCVs limits the advantage of Prn-deficient isolates. Conversely, if the immune response is directed against a limited number of antigens (one to five in the case of ACVs), non-expression of one of the vaccine antigens may confer a considerable selective advantage. This is especially the case when high antibody titres are induced, as is observed for ACVs [38]. However, further studies are required to substantiate this hypothesis.

The emergence of Prn-deficient strains raises questions about its role in pertussis. An analysis of clinical symptoms caused by Prn-positive and Prn-negative isolates in infants did not reveal major differences between the two groups, which suggests that lack of Prn in B. pertussis does not affect virulence in infants substantially [29]. Other important questions that should be addressed in the future are the effect, if any, of Prn-deficiency on the efficacy of pertussis vaccines and whether Prn-deficient strains prevail more in groups with a particular level of immunity. This study establishes a baseline for investigations into the emergence and spread of Prn-deficient strains in Europe.

This project was supported by the National Institute of Public Health and the Environment (RIVM), The Netherlands (SOR project S/230456). All the authors are members of the European research programme for improved pertussis strain characterisation and surveillance (EUPERTSTRAIN) network.

Conflict of interest
None declared.

Authors’ contributions
FRM obtained funding and supervised the study. QH and JM organised the EUPERTSTRAIN 2 and 3 collections from the network members. Isolates, epidemiological data and isolate characteristics were provided by all authors. AZ, MvG, KH, HvdH, MB and FRM were responsible for the study concept and practical work. AZ and FRM analysed and interpreted data and wrote the manuscript. All authors were responsible for the critical revision of the manuscript.

  1. Berbers GA, de Greef SC, Mooi FR. Improving pertussis vaccination. Hum Vaccin. 2009;5(7):497-503.
  2. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008;3(3):329-39.
  3. Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol. 2010;10(1):36-49.
  4. Conyn van Spaendock MA, Van der Maas NA, Mooi FR. Control of whooping cough in the Netherlands: optimisation of the vaccination policy. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2012. RIVM report 215121002. Synposis available from: 
  5. Public Health England (PHE). Confirmed pertussis in England and Wales: data to end-December 2012. Health Protection Report. 2013;7(5). Available from: 
  6. Schmidtke AJ. Boney KO, Martin SW, Skoff TH, Tondella ML, Tatti KM. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis. 2012;18(8):1248-55. 
  7. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect. 2014;142(4):685-94. 
  8. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22(1):22-7.
  9. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, et al., Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047-52.
  10. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368(6):581-2.
  11. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454-6.
  12. Hallander HO, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS. 2009;117(12):912-22.
  13. Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, Lan R. Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol. 2012;12(2):492-5.
  14. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Mooi FR. Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One. 2012;7(9): e46407.
  15. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun. 2001;69(9):5520-8.
  16. Mooi FR, , van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15(8):1206-13.
  17. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine. 2009;27(43):6034-41.
  18. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, Shibayama K, et al. Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One. 2012;7(2): e31985.
  19. Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. Clin Microbiol Infect. 2012;18(9):E340-6.
  20. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol. 2012;19(10):1703-4.
  21. Queenan AM, Cassiday PK, Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med. 2013;368(6):583-4.
  22. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol. 2014;21(2):119-25.
  23. Advani A, Gustafsson L, Ahrén C, Mooi FR, Hallander HO. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine. 2011;29(18):3438-42.
  24. Kallonen T, Mertsola J, Mooi FR, He Q. Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR. Clin Microbiol Infect. 2012;18(10):E377-9.
  25. Petersen RF, Dalby T, Dragsted DM, Mooi F, Lambertsen L. Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010. Emerg Infect Dis. 2012;18(5):767-74.
  26. Shuel M, Jamieson FB, Tang P, Brown S, Farrell D, Martin I, et al. Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone. Int J Infect Dis. 2013;17(6):e413-7.
  27. King AJ, van der Lee S, Mohangoo A, van Gent M, van der Ark A, van de Waterbeemd B. Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains. PLoS One. 2013;8(6):e66150.
  28. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis. 2009;49(10):1565-9.
  29. Bodilis H, Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis. 2013;19(3):471-4.
  30. van Loo IH, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40(6):1994-2001.
  31. van Gageldonk PG, van Schaijk FG, van der Klis FR, Berbers GA. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods. 2008;335(1-2):79-89.
  32. van Gent M, van Loo IH, Heuvelman KJ, de Neeling AJ, Teunis P, Mooi FR. Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One. 2011;6(3):e18014.
  33. Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, et al. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A. 1986;83(13):4631-5.
  34. Hijnen M, Mooi FR, van Gageldonk PG, Hoogerhout P, King AJ, Berbers GA. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun. 2004;72(7):3716-23.
  35. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Kallonen T, He Q, et al. SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One. 2011;6(5):e20340.
  36. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis. 2012;205(8):1220-4.
  37. Weber C, Boursaux-Eude C, Coralie G., Caro V., Guiso N. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol. 2001;39(12):4396-4403.
  38. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A controlled trial of two acellular vaccines and one whol cell vaccine against pertussis. N Engl J Med. 1996;334(6):341-8.
  39. Andersen PH, Knudsen LK, Valentiner-Branth P. DTAP-IPV/HIB vaccination coverage 2011. Copenhagen: Statens Serum Institut; 2012. EPI-news. No 23a. Available from: 
  40. van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol. 2005;43(6):2837-43.
  41. Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012;30(3):544-51.
  42. Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol. 2013;51(2):422-8.
  43. Campbell H, Amirthalingam G, Andrews N, Fry NK, George RC, Harrison TG, Miller E. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18(1):38-47.
  44. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 2005;1(4):e45.
  45. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66(2):670-5. 


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.